問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Surgery

National Cheng Kung University Hospital Dou-Liou Branch (在職)

Division of Hematology & Oncology

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital (在職)

更新時間：2023-09-19

吳尚殷Wu, Shang-Yin
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • wusy.tw@gmail.com

Recruiting Trial

272Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳尚殷

List

478Cases

2019-09-01 - 2024-12-31

Phase I/II

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    BA3021

Participate Sites
4Sites

Recruiting4Sites

2021-05-01 - 2024-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2021-04-01 - 2024-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-01-15 - 2028-12-31

Phase I/II

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)

  • Condition/Disease

    Non-Small-Cell Lung

  • Test Drug

    Tecentriq Avastin Docetaxel Accord Ipatasertib Trajenta Sacituzumab Govitecan

Participate Sites
2Sites

Not yet recruiting1Sites

Recruiting1Sites

2019-04-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting1Sites

Terminated7Sites

2019-04-01 - 2022-12-31

Phase II

A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs)

  • Condition/Disease

    non-squamous non-small cell lung cancer

  • Test Drug

    Durvalumab、Tremelimumab

Participate Sites
8Sites

Recruiting8Sites

夏德椿
China Medical University Hospital

Division of General Internal Medicine

2018-10-01 - 2022-12-31

Phase II

Pembrolizumab for Nasopharyngeal Carcinoma Patients With Detectable Plasma Epstein-Barr Virus DNA But Without Clinically Detectable Residual Diseases and/or Metastases After Curative Chemoradiation - A Single Arm Phase II Trial

  • Condition/Disease

    Nasopharyngeal Carcinoma

  • Test Drug

    Pembrolizumab (MK3475)

Participate Sites
8Sites

Recruiting5Sites

Terminated3Sites

2021-03-02 - 2024-06-16

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-06-08 - 2021-01-31

Phase II

A Phase II, Randomized, Blinded, Placebo-Controlled Study of Tiragolumab, An Anti-TIGIT Antibody, In Combination With Atezolizumab In Chemotherapy-Naïve Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    MTIG7192A (RO7092284)

Participate Sites
6Sites

Terminated6Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

江起陸
Taipei Veterans General Hospital

Division of Thoracic Medicine

2020-05-01 - 2025-05-31

Phase III

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

  • Condition/Disease

    A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

  • Test Drug

    TAK-788 (AP32788)

Participate Sites
9Sites

Recruiting9Sites

1 31 32 33 34 35 48
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB